Precision Scientific Completes Tens of Millions RMB B+ Financing to Enhance Capabilities as a Novel R&D Partner for Pharma Companies

VCBeat learned第一时间 that recently, Precision Scientific (Beijing) Co., Ltd. ("Precision Scientific") has completed a multi-million yuan B+ round of financing, invested by SUZHOU HIGH-TECH VENTURE CAPITAL GROUP CO.,Ltd. ("SUZHOU HIGH-TECH VENTURE").

This B+ round of financing, following the B round in September 2021, is another financing completed by the company within four months, which will help the company accelerate AIBERT.^®(Upgrade of the Tumor Multi-Omics Data Mining System for New Drug R&D) Platform, including the construction of the computing module (bioinformatics platform) and the experimental module (multi-omics functional laboratory). As a "new type of R&D partner for pharmaceutical companies," Precision Scientific gained more recognition from pharmaceutical companies in 2021. It successfully helped clients formulate differentiated new drug development strategies, focusing on the clinical value and market potential after product approval, advancing the R&D pipeline, and breaking through the trap of homogenized research. Within a year, the number of clients tripled. This round of financing enables the company to provide more comprehensive translational medicine services to more pharmaceutical partners, helping them build innovative and differentiated pipelines.

Dr. Ji Xuwo, Founder and CEO of Precision ScientificExpressed: "Thank you to SUZHOU HIGH-TECH VENTURE CAPITAL GROUP CO.,Ltd. for recognizing and supporting Precision Scientific. Whether it is the centralized procurement in China or the FDA’s reflection on ‘The Wild West of Checkpoint Inhibitor Development,’ it all points to the fact that new drug development must focus on addressing unmet clinical needs (diseases) by providing differentiated solutions (including the selection of drug molecules) to benefit patients. This marks a shift from a ‘molecule-oriented’ approach to a ‘disease-oriented’ one in new drug research. This is a formidable challenge, requiring us to systematically enhance our understanding of complex life systems and better analyze the overall regulatory networks of diseases (such as cancer), thereby improving our ability to evaluate and discover targets, indications, and biomarkers at the molecular mechanism level. With the rapid growth of data generated by multi-omics technologies (e.g., single-cell sequencing, expression profiling) and advancements in AI algorithms such as deep learning and causal inference, we are, for the first time in history, able to start from data to find this ‘answer’ (systemic capability). This allows us to gain deeper insights into the diseases (clinical problems) we aim to address and apply this ‘new knowledge’ to new drug development, turning more innovative and differentiated therapies into reality. We are thrilled to be taking the lead in this step and supporting our pharmaceutical partners in advancing their R&D pipelines to achieve encouraging results."Professor Han Liang, Co-founder of the CompanyIt was also emphasized: "Over the past decade, multi-omics of clinical samples represented by The Cancer Genome Atlas (TCGA), functional omics represented by DepMap, and single-cell omics represented by the Human Cell Atlas (HCA) have provided a rich data foundation, systematic approaches, and increasingly mature analytical technologies for understanding the essence of diseases and developing effective treatment strategies. This has made the vision of Precision Scientific possible—combining the most valuable omics data with the most advanced artificial intelligence algorithms to fully empower partners, thereby providing strong momentum for China's new drug development and precision medicine practices."

Dr. Miao Lv, Founding Partner of SUZHOU HIGH-TECH VENTURE CAPITAL GROUP CO., Ltd. Rongsheng Management CompanySaid: "At present, China's innovative drug research and development has entered the deep-water zone, and the bioinformatics analysis-driven differentiated new drug R&D strategy has become a 'must-have tool' for Bio Pharma and Biotech to avoid 'involution.' Precision Scientific owns a bioinformatics analysis team with internationally leading standards, and its self-developed AIBERT..."^®A multi-omics data mining platform can help biopharmaceutical R&D companies efficiently address the 'pain points' in differentiated development such as target evaluation, indication selection, biomarker discovery, and drug resistance mechanism research. The recently established multi-omics functional experiment team will further enhance AIBERT.^®The service efficiency. We are optimistic about the broad application prospects of in-depth bioinformatics analysis, and believe that under the leadership of Dr. Ji Xu and Professor Liang Han, Precision Scientific will continue to deliver its unique value in translational medicine services, contributing to the burgeoning biopharmaceutical innovation in China.

Precision Scientific's latest round of financing will further strengthen the construction of its technology platform, advance R&D collaborations with pharmaceutical partners, and provide comprehensive support based on multi-omics and data mining for the entire lifecycle of new drug development. We look forward to more talented individuals joining the passionate, driven, and action-oriented team at Precision Scientific to contribute to the exciting mission of "Omics data mining to drive new drug development."

Precision Scientific is a novel platform company driven by "multi-omics + data mining," focusing on differentiated R&D strategies for innovative drugs. The company, with advanced multi-omics technology, bioinformatics, and AI algorithms at its core, is based on its independently developed AI-driven massive multi-omics data mining system AIBERT.^®Precision Scientific provides innovative services to pharmaceutical and biotech companies, including world-leading drug mechanism research, biomarker discovery, differentiated R&D strategies based on biomarkers, clinical statistics, central laboratory services, and companion diagnostic development. It has established in-depth cooperation with several leading domestic and international pharmaceutical and biotech companies, facilitating the development and approval of multiple new drugs. Meanwhile, the company also collaborates with pharmaceutical companies and doctors at the clinical level to form a cooperative ecosystem, providing advanced testing services to patients and supporting the clinical practice of precision medicine.

SUZHOU HIGH-TECH VENTURE CAPITAL GROUP CO., Ltd., as a professional equity investment institution, has an investment team specializing in the full process of private equity investment funds: fundraising, investment, management, and exit. Based in Suzhou High-tech Zone and serving all of China, the group focuses on the goal of "strongly supporting the development of regional real economy and building a main industrial innovation base with the most concentrated innovative resources, the most active innovation ecosystem, and the most efficient innovation synergy." It has established a venture capital fund system covering different stages of corporate growth, including angel investment, VC, PE, industrial investment, and merger and acquisition investment, forming an equity investment chain and financial service chain that meet diversified corporate financing needs. In recent years, SUZHOU HIGH-TECH VENTURE CAPITAL GROUP has aligned with the "2+6+X" modern industrial layout of Suzhou High-tech Zone, focusing on cutting-edge economic fields such as biomedicine (medical devices), next-generation information technology, integrated circuits, high-end equipment manufacturing, green low-carbon, and digital economy. The group has set up more than 70 funds with a total subscribed scale reaching hundreds of billions of yuan, cumulatively investing in over 700 high-quality projects, including GoodWe (688390), Hillstone Networks (688030), ShangLuo Electronics (300975), and Huatong Cable (605196).